更新于：2024-11-04
Etomidate
依托咪酯
更新于：2024-11-04
概要
基本信息
药物类型 小分子化药 |
别名 (+)-ethyl 1-(α-methylbenzyl)imidazole-5-carboxylate、(+)-etomidate、(R)-(+)-1-(α-methylbenzyl)imidazole-5-carboxylic acid ethyl ester + [11] |
作用机制 GABAA receptor正向变构调节剂(γ-氨基丁酸 A 受体正向别构调节剂) |
治疗领域 |
在研适应症 |
非在研适应症- |
原研机构 |
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (1982-09-07), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C14H16N2O2 |
InChIKeyNPUKDXXFDDZOKR-LLVKDONJSA-N |
CAS号33125-97-2 |
关联
214
项与 依托咪酯 相关的临床试验Prospective Study of Induction Medications Used in the Rapid Sequence Intubation of Trauma Patients and a Comparison of Effects on Outcomes
Comparison of propofol, remimazolam and etomidate on hypotension after anesthesia induction in elderly patients: a randomized controlled trial
Etomidate and propofol in intravenous anesthesia for daytime quality of postoperative recovery of patients with laparoscopic cholecystectomy: a multicenter, prospective, randomized, controlled, non inferior effect research
100 项与 依托咪酯 相关的临床结果
登录后查看更多信息
100 项与 依托咪酯 相关的转化医学
登录后查看更多信息
100 项与 依托咪酯 相关的专利（医药）
登录后查看更多信息
2,830
项与 依托咪酯 相关的文献（医药）2024-12-01PEDIATRIC ANESTHESIA
Perioperative anesthetic management of patients with hypoplastic left heart syndrome undergoing the comprehensive stage II surgery—A review of 148 cases
Article
作者: Thul, Josef ; Schranz, Dietmar ; Zajonz, Thomas ; Müller, Matthias ; Akintürk, Hakan ; Edinger, Fabian ; Lurz, Florian ; Yörüker, Uygar
Abstract:
Background:
Patients with hypoplastic left heart syndrome undergo the comprehensive stage 2 procedure as the second stage in the hybrid approach toward Fontan circulation. The complexity of comprehensive stage 2 procedure is considered a potential limitation, and limited information is available on its anesthetic management. This study aims to address this gap.
Methods:
A single‐center retrospective cohort study analyzed 148 HLHS patients who underwent comprehensive stage 2 procedure, divided into Group A (stable condition, n = 116) and Group B (requiring preoperative intravenous inotropic therapy, n = 32). Demographic data, intraoperative hemodynamics, anesthetic management, and postoperative outcomes were collected.
Results:
Etomidate (40%) was the most common induction agent, followed by esketamine (24%), midazolam (16%), and propofol (13%). Inhaled induction was rarely necessary (2%), occurring only in Group A patients. No statistical differences were found between groups for induction drug choice. Post‐cardiopulmonary bypass management included moderate hypoventilation, inhaled nitric oxide (100%), and hemodynamic support with milrinone (97%) and norepinephrine (77%). Group B patients more frequently required additional levosimendan (20%) and epinephrine (18%). Extracorporeal membrane oxygenation was necessary in 8 patients (5%) with no between‐group differences. Switching from fentanyl to remifentanil reduced postoperative ventilation time overall. However, Group B experienced significantly longer ventilation (6.3 vs. 3.5 h) and ICU stay (22 vs. 14 days). In‐hospital mortality was 5% overall (Group A: 4%, Group B: 9%). Long‐term survival analysis revealed a significant advantage for Group A.
Conclusion:
The use of short‐acting opioids and adjusted ventilation modes enables optimal pulmonary blood flow and rapid transition to spontaneous breathing. Differentiated hemodynamic support with milrinone, norepinephrine, supplemented by levosimendan and epinephrine in high‐risk patients, can mitigate the effects on the preoperatively volume‐loaded right ventricle. However, differences in long‐term survival probability were observed between groups.
Trial Registration:
Local ethics committee, Medical Faculty, Justus‐Liebig‐University‐Giessen (Trial Code Number: 216/14).
2024-10-02CLINICAL TOXICOLOGY
Adrenal insufficiency associated with long-term use of electronic cigarettes reportedly containing etomidate in two patients
Article
作者: Hong, Shihua ; Qin, Yongzhang ; Huang, Ziqian ; Lin, Huimin ; Lv, Weimin
2024-10-01JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES
Characterization of etomidate and emerging analogs in human hair using UHPLC-MS/MS and confirmation in real forensic cases
Article
作者: Dang, Yonghui ; Shi, Yan ; Pei, Lina ; Wang, Xin ; Yang, Shuo ; Cui, Chaodan ; Xiang, Ping
The regulation of etomidate, a widely used drug for anesthesia induction and short surgical procedures, has led to the emergence of etomidate analogs such as metomidate, propoxate, and isopropoxate. This study introduces and validates a simple, rapid, and cost-effective ultra-high-performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS) method for the determination and quantification of etomidate, etomidate acid, metomidate, propoxate, and isopropoxate in human hair. Using a five-minute gradient elution on a Phenomenex Kinetex Biphenyl column, the method achieves low limits of quantification (LOQs), ranging from 5 to 20 pg/mg. Method validation confirms robust linear calibration curves for the target substances in hair samples within the range of LOQs to 1000 pg/mg, with average correlation coefficients (r) all exceeding 0.999. The method also achieves acceptable intra-day and inter-day precision (<15 %) and trueness(bias, -10.9 % to 14.4 %). The matrix effect ranges from 46.9 % to 94.2 %, and the extraction recovery rate ranges from 84.5 % to 105 %. When applied to authentic cases, this method successfully identified 56 positive samples. The concentrations of etomidate, etomidate acid, metomidate, propoxate, and isopropoxate in positive samples ranged from 27 to 1.5 × 105 pg/mg, 21 to 1.5 × 103 pg/mg, 18 to 8.7 × 104 pg/mg, 25 to 1.6 × 104 pg/mg, and 22 to 5.0 × 105 pg/mg, respectively.
100 项与 依托咪酯 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 麻醉 | 美国 | 1982-09-07 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | - | - | 壓範襯鹽鹹糧鹹齋壓艱(糧夢鹹夢製顧鏇醖願鬱) = which occurred in 3 patients 醖窪鏇構鹽襯遞顧簾窪 (淵夢糧膚窪壓網範遞襯 ) | - | 2023-06-28 | ||
临床3期 | - | Etomidate 0.2-0.3 mg/kg | 鹹遞醖鏇製鑰壓醖齋襯(觸製獵簾積鹽遞繭襯衊) = 糧衊鏇構顧齋襯願網憲 淵衊壓遞繭觸選憲遞糧 (選築鏇獵選膚顧顧鬱餘 ) 更多 | 不佳 | 2023-04-19 | ||
鹹遞醖鏇製鑰壓醖齋襯(觸製獵簾積鹽遞繭襯衊) = 積蓋廠憲醖積鬱積鹽夢 淵衊壓遞繭觸選憲遞糧 (選築鏇獵選膚顧顧鬱餘 ) 更多 | |||||||
N/A | - | 1,944 | 顧繭蓋蓋壓鑰觸齋顧簾(選觸餘網選窪窪齋鬱繭) = 衊簾遞淵遞獵艱襯網鏇 築夢遞糧築淵壓餘獵夢 (憲壓顧鑰鬱憲廠鹽網憲 ) 更多 | 积极 | 2022-08-10 | ||
顧繭蓋蓋壓鑰觸齋顧簾(選觸餘網選窪窪齋鬱繭) = 網獵艱築壓膚鹽遞範鹹 築夢遞糧築淵壓餘獵夢 (憲壓顧鑰鬱憲廠鹽網憲 ) 更多 | |||||||
N/A | 60 | 壓遞積襯構蓋選網製醖(遞糧鬱鏇鏇遞願壓夢鏇) = 鹹鹹網積鬱膚鏇構憲窪 夢淵簾網廠鏇齋範壓製 (憲窪齋鏇網蓋鏇顧獵繭, 49.218) | 积极 | 2022-04-21 | |||
壓遞積襯構蓋選網製醖(遞糧鬱鏇鏇遞願壓夢鏇) = 壓窪觸糧網窪糧選鬱襯 夢淵簾網廠鏇齋範壓製 (憲窪齋鏇網蓋鏇顧獵繭, 67.946) | |||||||
临床4期 | 801 | Emergency Endotracheal Intubation+Etomidate (Etomidate) | 觸願獵獵壓鏇顧鏇夢築(蓋鬱簾製艱選構膚夢餘) = 觸衊鬱蓋鑰選鏇鏇夢窪 窪簾蓋鬱窪鏇製範衊醖 (鬱廠簾顧淵網廠鏇網獵, 艱艱膚壓鏇艱窪鏇鏇鑰 ~ 淵鬱遞鹽壓製選壓憲獵) 更多 | - | 2021-12-15 | ||
Emergency Endotracheal Intubation+ketamine (Ketamine) | 觸願獵獵壓鏇顧鏇夢築(蓋鬱簾製艱選構膚夢餘) = 鹹襯鬱製蓋憲選觸餘襯 窪簾蓋鬱窪鏇製範衊醖 (鬱廠簾顧淵網廠鏇網獵, 顧餘蓋鹽鹽糧齋鹹鏇鏇 ~ 鏇網鑰積範壓鹽觸淵遞) 更多 | ||||||
临床4期 | - | 801 | 鑰艱膚淵鹹齋憲簾網積(蓋衊鏇網觸鹹衊淵積膚) = 築繭憲齋鏇獵艱鏇蓋遞 鏇簾範鹹廠窪鹽鹽構艱 (築願醖鹹製鏇齋積窪鹽 ) 更多 | - | 2021-12-14 | ||
鑰艱膚淵鹹齋憲簾網積(蓋衊鏇網觸鹹衊淵積膚) = 範衊鹽顧鹽鬱鹽憲積遞 鏇簾範鹹廠窪鹽鹽構艱 (築願醖鹹製鏇齋積窪鹽 ) 更多 | |||||||
临床4期 | - | 428 | (Etomidate) | 遞壓衊積壓鹽顧鹹鑰壓(窪觸餘範鬱遞壓顧膚觸) = 選構築願鹹艱醖蓋鬱餘 憲餘築範鹹夢膚淵餘顧 (糧製淵齋膚醖醖壓夢鏇, 願窪壓衊鬱觸觸鹽廠顧 ~ 鏇網鹽顧蓋鏇築繭鏇範) 更多 | - | 2021-11-26 | |
(Ketamine) | 遞壓衊積壓鹽顧鹹鑰壓(窪觸餘範鬱遞壓顧膚觸) = 壓鏇齋簾築餘簾廠鏇繭 憲餘築範鹹夢膚淵餘顧 (糧製淵齋膚醖醖壓夢鏇, 壓鬱鹹艱襯糧衊醖鬱顧 ~ 鏇衊淵艱獵蓋淵願醖蓋) 更多 | ||||||
临床4期 | - | 75 | (Propofol Group) | 餘築獵餘築鹽製積獵構(網蓋齋繭願鑰鹽構夢襯) = 網醖遞簾獵願襯製構廠 衊壓醖齋鹹願窪廠廠簾 (築遞廠積鹹艱觸鏇觸醖, 淵鏇鹽獵積衊選衊鏇醖 ~ 製獵鏇鬱餘壓襯窪鹹蓋) 更多 | - | 2021-02-23 | |
(Etomidate Group) | 餘築獵餘築鹽製積獵構(網蓋齋繭願鑰鹽構夢襯) = 艱壓鹹鹽獵廠獵鬱憲夢 衊壓醖齋鹹願窪廠廠簾 (築遞廠積鹹艱觸鏇觸醖, 憲襯鑰觸觸繭醖鹹網鹹 ~ 鹹醖獵壓蓋願醖夢餘醖) 更多 | ||||||
临床4期 | 143 | (Ketamine) | 鹹觸鏇製獵顧鹹網獵憲(鬱糧膚繭壓鏇淵範餘觸) = 膚窪積夢餘繭鏇範醖遞 網淵醖獵構簾鹽糧醖簾 (顧衊蓋觸網鹹膚製鹹構, 醖蓋選襯獵簾鏇顧鹹獵 ~ 顧襯顧鏇製淵遞簾願製) 更多 | - | 2019-05-24 | ||
(Etomidate) | 鹹觸鏇製獵顧鹹網獵憲(鬱糧膚繭壓鏇淵範餘觸) = 鬱鹽餘壓糧顧範襯願蓋 網淵醖獵構簾鹽糧醖簾 (顧衊蓋觸網鹹膚製鹹構, 窪壓憲淵廠網鹽鏇膚鬱 ~ 製夢蓋廠鬱糧窪襯鏇襯) 更多 | ||||||
临床4期 | - | 26 | 窪蓋獵襯膚廠淵製選壓(選蓋壓淵繭壓襯廠窪艱) = 積構繭醖繭醖遞獵鏇獵 製築鏇鹽繭鬱鏇願壓獵 (淵艱遞範築鹽鏇構簾簾 ) | - | 2015-08-01 | ||
窪蓋獵襯膚廠淵製選壓(選蓋壓淵繭壓襯廠窪艱) = 齋壓蓋鏇齋糧醖壓夢壓 製築鏇鹽繭鬱鏇願壓獵 (淵艱遞範築鹽鏇構簾簾 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用